[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
about
Emerging PSA-based tests to improve screeningHow Precisely Can Prostate Cancer Be Managed?Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic diseaseDetection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessClinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureGlycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers.A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening studyProspective evaluation of operating characteristics of prostate cancer detection biomarkers.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerPro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Commercialized biomarkers: new horizons in prostate cancer diagnostics.Prostate-specific antigen-based prostate cancer screening: Past and future.Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients.Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen.Establishment of a mammalian expression system for recombinant [-2]proPSA and a specific antibody against the truncated leader peptide.Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml
P2860
Q26828563-ADC8DA71-2094-4E10-B45F-D7DC699C22CEQ28078942-5A515738-D0D2-439E-86CB-E97970ED3745Q33449075-9D8B0B7A-C742-40DF-AC43-C35AE2B013EBQ33609420-3734E213-8388-4ADE-BFED-4B9A2F8797C0Q33839248-DB7FDD24-1EE8-4635-B628-7E7F864E3CF2Q33911725-1EE53355-AB35-4E01-9E43-A753D18CC774Q34381513-CA35DE75-56D6-496D-8EB6-207704B9266EQ34495122-6CBFF593-C85C-4328-B078-20C66A95A9F4Q35119292-6BC336CC-C55A-4702-901E-29995FD3FF90Q35995359-3EA182F0-61CA-4D04-B943-61527D30FF55Q36266738-A3071A9A-74B2-4BE2-85A8-4B49716C1385Q36416441-55B0263A-7C07-4420-AC3F-87939E0D4DA6Q36509148-7E61481F-BC5B-4C49-A695-8BF62DA28311Q37252155-B403909F-6032-4F11-8E0E-6295F83D8FAAQ37300931-2C89277E-86BE-49A0-A5B6-8FE717187E1BQ37422990-74B270D8-6CAA-4101-A724-F14A927FE553Q37456021-6EDA526B-A543-4D16-A3F4-031DD15B85E1Q37460195-F59DEF1F-9FE8-473C-B699-3877F7CD25FFQ37685652-6A41B528-DC38-4B8E-925F-6AF7DE235191Q37738370-13207EC6-FEA8-45A3-B97D-C64E35ACBC33Q38023597-6769137C-926E-4704-9A31-ED7D836511F1Q38241107-5CAF432B-1932-4E3E-BA7B-BFCA755E2D19Q38364797-272BCBFB-9AF7-412C-A788-AD8F3FB5FA5BQ38408501-57D37059-BBD6-47BE-AE5D-9104A51860BCQ46098777-49F44DE5-E7A4-47A4-9C82-28347B56C4E1Q46201624-0588EEE7-EB37-49B3-8822-1C99E46C8460Q46569706-1DE95F0E-637B-4D2A-9EF7-E8A19382CC40Q51714928-F1AA4149-121B-447B-9566-5FE2FC5821FDQ53205255-75A9E936-0B42-4A43-A46D-A5EA1466477BQ57999041-A46133E1-8CF1-4BCF-9D79-873F0C2B5C37
P2860
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
[-2]proenzyme prostate specifi ...... arch network validation study.
@en
[-2]proenzyme prostate specifi ...... arch network validation study.
@nl
type
label
[-2]proenzyme prostate specifi ...... arch network validation study.
@en
[-2]proenzyme prostate specifi ...... arch network validation study.
@nl
prefLabel
[-2]proenzyme prostate specifi ...... arch network validation study.
@en
[-2]proenzyme prostate specifi ...... arch network validation study.
@nl
P2093
P2860
P1476
[-2]proenzyme prostate specifi ...... arch network validation study.
@en
P2093
Daniel W Chan
Ian M Thompson
Jacob Kagan
Lori J Sokoll
Martin G Sanda
Yinghui Wang
Ziding Feng
P2860
P304
539-43; discussion 543
P356
10.1016/J.JURO.2008.04.015
P407
P577
2008-06-11T00:00:00Z